Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancerNPJ Breast Cancer 2022 Aug 29;8(1)98, HS Rugo, SM Tolaney, D Loirat, K Punie, A Bardia, SA Hurvitz, J O'Shaughnessy, J Cortés, V Diéras, LA Carey, L Gianni, MJ Piccart, S Loibl, DM Goldenberg, Q Hong, M Olivo, LM Itri, K Kalinsky
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.